Harrow Launches Interchangeable BYOOVIZ Biosimilar to Penetrate $9B Retina Market
HROW•Harrow has commenced U.S. commercial sales of BYOOVIZ (ranibizumab-nuna), its first interchangeable ranibizumab biosimilar, under an exclusive partnership with Samsung Bioepis. The launch targets a $9 billion U.S. anti-VEGF market and complements Harrow’s retina portfolio alongside IHEEZO and TRIESENCE.
1. Harrow Launch Details
Harrow announced the commercial launch of BYOOVIZ (ranibizumab-nuna) in the United States, marking its first interchangeable biosimilar to LUCENTIS. The company obtained exclusive U.S. commercialization rights through a partnership with Samsung Bioepis and will market the product to retina specialists for wet AMD, RVO and mCNV indications.
2. Market Opportunity
BYOOVIZ enters an estimated $9 billion U.S. anti-VEGF market seeking therapies for sight-threatening retinal diseases. Its FDA designation as an interchangeable biosimilar aims to address prior supply inconsistencies and deliver economic value to healthcare providers and patients.
3. Strategic Portfolio Expansion
The launch bolsters Harrow’s retina franchise alongside IHEEZO (ocular anesthetic gel) and TRIESENCE (injectable corticosteroid). Harrow leverages its specialized commercial infrastructure and established relationships with retina practices to drive adoption of its growing buy-and-bill product suite.
